## In the Claims

- 1. (Currently amended) A method of treating peripheral pain in a subject in need thereof, comprising orally administering to the subject an effective amount of a substantially monodispersed mixture of conjugates, wherein the conjugate comprises a first oligomer and a second oligomer, wherein each oligomer is coupled to salmon calcitonin and wherein the first oligomer is covalently coupled to an amine group of Lys<sup>11</sup> of the salmon calcitonin and the second oligomer is covalently coupled to an amine group of Lys<sup>18</sup> of the salmon calcitonin, wherein the amino acid sequence of the salmon calcitonin is SEQ ID NO. 1.
- 2. (Previously prevented) A method of treating peripheral pain in a subject in need thereof, comprising orally administering to the subject an effective amount of a substantially monodispersed mixture of conjugates, each conjugate comprising a calcitonin drug coupled to an oligomer that comprises a polyethylene glycol moiety, wherein the oligomer comprises a first polyethylene glycol moiety covalently coupled to the calcitonin drug by a non-hydrolyzable bond and a second polyethylene glycol moiety covalently coupled to the first polyethylene glycol moiety by a hydrolyzable bond.
- 3. (Currently amended) A method of treating peripheral pain due to a bone disorder in a subject in need thereof, comprising orally administering to the subject an effective amount of a substantially monodispersed mixture of conjugates each comprising salmon calcitonin covalently coupled at Lys<sup>11</sup> of the salmon calcitonin to the carboxylic acid moiety of a carboxylic acid, which is covalently coupled at the end distal to the carboxylic acid moiety to a methyl terminated polyethylene glycol moiety having at least 7 polyethylene glycol subunits, and covalently coupled at Lys<sup>18</sup> of the salmon calcitonin to the carboxylic acid moiety of a carboxylic acid, which is covalently coupled at the end distal to the carboxylic acid moiety to a methyl terminated polyethylene glycol moiety having at least 7 polyethylene glycol subunits, wherein the amino acid sequence of the salmon calcitonin is SEQ ID NO. 1.

Claims 4.-13. (Cancelled).

In re Appln. of VERSCHUEREN et al. Application No. 10/068,519

Even more, the image-forming layer by Love is a uniform hydrophobic layer which has a layer thickness as thin as possible to be easily ablated by laser exposure, by preference a monomolecular layer is used (see col. 7 lines 32-col. 8 line 1). The image-forming layer by Vermeersch is much thicker, namely in the range of  $3.36g/m^2$  (comprising polymer particles with an average diameter of 90 nm) as demonstrated in Example 1 on col. 15 lines 17-35. This means for the skilled person that the image-forming layer of Vermeersch is not suited to be easily ablated as taught by Love.

There is no suggestion in Love to combine the ablation method with the image-forming system of Vermeersch. On the contrary, there is a teaching away by Love in using the system of Vermeersch: "the formation of the latent image does not depend upon any photo-induced reaction, for example polymerization, cross-linking, or indeed any kind of chemical reaction as would be used to harden, soften, or otherwise cure a hydrophilic or hydrophobic layer, or render such layer either soluble or insoluble" (see col. 11 lines 47-55 and see also col. 13 lines 34-37).

In the background of the present invention, the ablation method of Love is mentioned but this system has the disadvantage of damaging the lithographic surface of typical substrates such as grained and anodized aluminum due to the very temperature that is generated in ablated lithographic coating (see present invention on page 4 lines 9-13). This damaging effect is also demonstrated in the comparative example 1 on page 14-16, reduced printing quality due to staining after 1 cycle (see results on pages 18-19). The present invention, however, "allows effective removal...in a large number of printing cycles, preferably larger than 5" (see page 4 lines 26-33). So it is clear that the present invention contains an inventive step and is not obvious over Vermeersch in view of Love.

The Office Action further rejected claims 4-6 and 8 based upon, *inter alia*, the combination of Love and Vermeersch. For the reasons set forth in the preceding paragraphs in opposition to this combination, withdrawal of the rejection is respectfully requested. Based on the same arguments as mentioned for the Rejection of claims 1-3, 7, 9 and 10, we argue that it is not obvious to combine Love with Vermeersch and therefore the claims 4-6 and 8 are new and inventive.

## Conclusion

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

In re Appln. of VERSCHUEREN et al. Application No. 10/068,519

Respectfully submitted,

Christopher T. Griffith, Reg. No. 33,392 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: September 19, 2003

Amendment or ROA - Regular (Revised 7/29/03)